VEDANTA BIOSCIENCES INC.

History

Year	Detail
2010	Vedanta Biosciences, a biotechnology company that develops oral therapies to treat diseases, was founded in 2010 by PureTech Health and a group of scientific experts. The founders include Alexander Rudensky, Bernat Olle, Dan Littman, David Steinberg, and Ruslan Medzhitov.
2022	The company established a new manufacturing facility to provide clinical and commercial supply for its therapeutic portfolio, including for the planned Phase 3 study and commercial launch of its lead candidate, VE303, in Clostridioides difficile infection.
2024	The company was awarded $3.9 million in funding from the global nonprofit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance Vedanta’s VE707 preclinical development program for reducing colonization and preventing subsequent infections caused by multidrug-resistant organisms (MDROs).

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment